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Abstract
Head and neck (HN) cancer represents one of the most challenging diseases because the mortality
remains high despite advances in early diagnosis and treatment. Although vaccine-based approaches
for the treatment of advanced squamous cell carcinoma of the head and neck have achieved limited
clinical success, advances in cancer immunology provide a strong foundation and powerful new
tools to guide current attempts to develop effective cancer vaccines. This article reviews what has
to be rather what has been done in the field for the development of future vaccines in HN tumours.
Review
The concept that a vaccine could be useful in the treat-
ment of cancer diseases is a long-held hope coming from
the observation that patients with cancer who developed
bacterial infections experienced remission of their malig-
nancies. In 1896, New York surgeon William Coley locally
injected streptococcal broth cultures to induce erysipelas
in a patient with an inoperable neck sarcoma, obtaining a
tumour regression. Although the therapy was toxic, the
patient's tumour ultimately regressed, and he lived dis-
ease-free for 8 years before succumbing to his cancer [1].
During the century since Coley's first experiments,
immensely more is understood about tumour immunol-
ogy: the validation of the theory of cancer immunosur-
veillance, the definition of a large number of tumour
antigens as targets for immune recognition, the prognostic
significance of immunological parameters, such as the dif-
ferent sub-classes of T cell infiltrating human tumours,
and therapeutic benefits of immune-related therapies
from BCG to anti-CTLA-4 are the major achievements that
pose the theoretical basis to test the validity of cancer vac-
cines. In particular some characteristics of HNSCC render
these tumours susceptibly to explore efficacious immuno-
therapy: the presence of well characterized Tumour Asso-
ciated Antigens (TAA) and the possibility to perform
clinical trials as adjuvant cancer therapy to eradicate local
regional microscopic and micrometastatic disease with
minimal toxicity to surrounding normal cells.
TAA
HNSCC cells, as in general tumour cells, express both
unique and shared antigens capable of being recognized
by T cells. Identification of CTL epitopes presented by
major histocompatibility complex (MHC) class I mole-
cules on tumour cells is vital for the design of active
immunotherapy. Many antigens have been identified so
far by utilising well characterized approaches already uti-
lised for other tumours. These approaches are:
￿ A peptide-elution approach involving the biochemi-
cal elution of peptides from the binding cleft of
tumour HLA molecules, and pulsing these peptides
onto APC to test their ability to sensitize target cells for
lysis by specific antitumour lymphocytes.
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￿ A reverse immunology approach predicting possible
antigenic peptide sequences from oncogenes or
tumour-associate proteins using known HLA-anchor
motifs, followed by an in vitro investigation of the abil-
ity of the predicted synthetic peptides to stimulate T
lymphocytes.
￿ A serological approach involving the identification
of antigens by recombinant expression cloning
(SEREX) [2]. SEREX was developed to combine sero-
logical analysis with antigen cloning techniques to
identify human tumour antigens eliciting autologous
high-titer immunoglobulin G (IgG) antibody
responses.
￿ A genetic approach involving two different methods:
i) the transfection of cDNA libraries from tumour cells
into target cells expressing the appropriate human leu-
kocyte antigen (HLA) molecule, and then screening
transfected cells for stimulating CD8+ T-cell clones
from cancer patients; ii) the microarray analyses facil-
itating the individuation of differential highly
expressed genes in HN primary tumour samples [3].
The TAAs that have been described in HNSCC cells are
derived from a broad spectrum of intracellular proteins
and have bee exhaustively reported in other reviews [3-5].
In principle a complete arrays of TAA antigens can be
obtained by immunizing with a heterogeneous mixture of
tumour antigens, using irradiated tumour cells themselves
or tumour-derived materials such as tumour cell lysates or
apoptotic (killed) tumour cells as substrates for generat-
ing antitumour immune responses. This approach failed
to be effective for many reasons and, mostly, for the clear
hurdle represented by the reliance on the proper internal-
ization, processing and antigen presentation by immune
cells in which these machineries are already altered in
tumour-bearing patients.
In a single patient a particular TAA, not broadly shared
among other HNSCC patients, may be detected but the
procedures are so laborious to render this approach
impractical in clinical application of vaccines.
Significant advances in molecular genetic technology are
facilitating the identification of numerous TSAs in head
and neck cancer, which try to meet some criteria of an
ideal TAA. The ideal TAA must have an unique expression
within the tumour or a differential expression as com-
pared to normal tissue or vital organs; it has to be
expressed by a majority of head and neck cancers; it
should be constitutively expressed and maintained during
carcinogenesis; and finally it should be highly immuno-
genic. To date TAAs matching almost all of these criteria
are the human papillomavirus (HPV) E6 and E7 proteins.
The association of HPV with HNSCC and the utilisation of
viral oncoprotein for immunotherapy has been reviewed
elsewhere [6].
Briefly HPV is associated with approximately 20–25% of
all HNSCC and up to 60–70% of those tumours localized
to the oropharynx, in particular tonsil [7]; the HPV type
16 has been found in more than 90% of HPV-positive
HNSCC; the E6 and E7 proteins are constitutively
expressed and maintained during the HPV-associated car-
cinogenesis; and the viral oncoproteins are foreign anti-
gens and, therefore, are highly immunogenic.
Beside the matching to an ideal TAA the HPV E6 and E7
proteins serve as model antigens for the development of
immunotherapy and since HPV type 16 is also associated
with cervical and anogenital cancers, the same vaccine
strategies developed to prevent (already in clinical use)
and/or to treat HPV-associated cervical and anogenital
cancers can also be used in head and neck cancers [for
review see [6,8]]. Nevertheless these oncoproteins account
for only 20% of HNSCC and enforces must be done to
identify other TAAs in the remaining HNSCC matching
closely all the above mentioned criteria. In this filed an
enormous work has been done but before some of these
TAAs becomes valid therapeutic vaccine other hurdles
must be overcome, the tumour immune escape and
tumour tolerance.
Tumour immune escape and tolerance
The discovery of so powerful TAAs in HNSCC is giving
substantial basis for efficacious and less toxic treatments,
but in the mean time HNSCC as other tumours partici-
pates in tumour immune escape through various mecha-
nisms:
i) it disrupts antigen processing and presentation
machinery by altering the MHC class I and TAP 1–2
expression;
ii) it recruits immunosuppressive Treg to dampen
effector T-cell activity,
iii) by chemokine production it alters T-cell homeos-
tasis increasing the sensitivity of effector T cells to
apoptosis.
Downregulation of antigen-processing machinery (APM)
components, such as TAP 1/2 and MHC class I antigens,
renders ineffective the recognition by CTL in HNSCC.
More than 50% of primary and metastatic lesions showed
MHC class I antigen loss [9]. Interestingly, interferon-γ
(IFN-γ), which functions to up-regulate APM and MHC
molecules, can restore in vitro the ability of specific CTLs
to recognize their tumour cell targets and subsequently toJournal of Experimental & Clinical Cancer Research 2009, 28:69 http://www.jeccr.com/content/28/1/69
Page 3 of 11
(page number not for citation purposes)
lyse them [10,11]. Thus in a therapeutic setting clinical
efforts must be undertaken in order to restore APM and
MHC class I antigen expression in HNSCC.
The complex biology of CD4+CD25+FoxP3+ regulatory T
cells (Treg), which function to downmodulate immune
responses and have enormous implications on the devel-
opment of cancer immunotherapies, is far to be fully
understood.
Tumour cells are believed to recruit Treg within the tumour
microenvironment to suppress antitumour immunity.
Analyses of tumour-infiltrating lymphocytes revealed a
greater percentage of Treg in HNSCC compared with the
circulating counterpart of both patient and healthy controls
[12], suggesting that in HNSCC Treg cells are recruited in
the tumour area respect to the lymphnode or circulating
location. Recently, it has been reported that naïve antigen-
specific T cells can be either activated or tolerized simulta-
neously in the same host, depending on the microenviron-
ment in which the epitope is presented [13]. Effector T cells
generated in lymph nodes are tolerized rapidly when they
infiltrate antigen-expressing tumour tissues. Interestingly,
tolerant T cells persist only in the tumours and resemble
tumour infiltrating lymphocytes seen in cancer patients
[14]. In the clinical setting the effect of Treg may be attenu-
ated by depleting them with non-myeloablative chemo-
therapy or monoclonal antibodies against inhibitory
receptors (anti-CTL antigen-4 [CTLA4]) [15,16]. In various
mouse models antibodies against the glucocorticoid-
induced tumour necrosis factor receptor family (GITR) are
able to downregulate Treg functions increasing the efficacy
of immunotherapies [17,18]
However the role of the human counterpart of this recep-
tor huGITR appears to be quite different with less activity
on Treg suppression [19,20]
Controlled and effective modulation of Treg cell function
for cancer therapeutics will be contingent on a better
understanding of the molecular basis of Treg cell interac-
tion with tumour cells and ensuing immunosuppressive
mechanisms. A study using a synthetic monoclonal anti-
body targeted against CD28 met with disastrous results,
reminding us that manipulation of costimulatory/regula-
tory pathways requires more information in this field
[21].
Nevertheless continuing investigation on the biology of
Treg in antitumour immunity and potential toxicities of
Treg suppression will undoubtedly implement the efficacy
of cancer immunotherapies.
Finally in patients with HNSCC the absolute number of T-
lymphocytes both CD4+ and CD8+ is reduced and it may
be related with a decrease expression of chemokine recep-
tor 7 (CCR7) on T cells [22]. CCR7 has been implicated in
protecting CD8+ T cells from apoptotic cell death. Indeed
CD8+ CCR7-negative T lymphocytes that are more sensi-
tive to apoptosis were increased in HNSCC patient
peripheral blood compared with healthy controls [22].
These are the major barriers that have to be broken by an
effective therapeutic vaccine. Before reaching the toler-
ance or tumour escape a therapeutic vaccine must elicit a
strong cellular immune response involving the CD4 and
CD8 stimulation.
Many strategies have been developed to induce a response
against the TAA. In particular the HPV E7 antigen has been
utilised to develop an incredible large number of different
possible therapeutic vaccines extensively reviewed else-
where [6]. The basic strategy to induce a specific anti-TAA
response has been applied also for the non-viral HNSCC
TAA and are briefly discussed.
Peptide/protein based vaccines
To date, several peptide-based vaccines are either undergo-
ing clinical evaluation or are in development. A major lim-
itation to peptide-based vaccines is the need to identify the
immunogenic epitope of the tumour-associated antigen.
The observation that the antigenic epitope with the highest
binding affinity to the HLA molecule does not necessarily
correlate with its potential immunogenicity in vivo
decreases the applicability of these peptide based vaccines.
Thus, MHC molecules may restrict the candidacy for this
approach, making difficult to carry out large scale vaccina-
tion treatment schemes. The HLA restriction associated
with peptide-based vaccines can be overcome with the use
of whole protein-based vaccines, harbouring multiple
immunogenic epitopes which can bind the various allelic
HLA molecules. However, due to the poor immunogenicity
of both peptides and proteins most of the researches in this
area have focused on the co-administration of adjuvant
immune-enhancing agents such as chemokines, cytokines,
and costimulatory molecules to enhance the potency of the
vaccine [for a review, see [3,23]]. Chimeric GM-CSF mole-
cules can enhance antigenic immune responses through
the recruitment of antigen present cells [24,25]; co-admin-
istration of immunostimulatory CpG oligodeoxynucle-
otides may be able to stimulate macrophages to secrete IL-
12 shifting the cytokine profiles to a Th1-type cell-mediated
immune response [26,27]. Recently the fusion of the beta-
1,3–1,4-glucanase (LicKM) of Clostridium thermocellum
bacterial protein to the HPV E7 protein produced an anti-
gen with strong intrinsic adjuvating activity, indicating that
manipulation of the antigen may elicit some unknown
helpful function [28,29]
The results of clinical trials indicate that peptide/protein
vaccination has low toxicity but a strong discordance
exists between immune and clinical responses, reinforcingJournal of Experimental & Clinical Cancer Research 2009, 28:69 http://www.jeccr.com/content/28/1/69
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the need of further improvement to the vaccination by the
utilization of peptide-pulsed dendritic cells, the addition
of helper peptides, and depletion of Treg. Several phase I
clinical trials using antigenic peptides derived from HPV
E6/E7 have been so far conducted as well as multivalent
peptide-based vaccination against p53 [30-32] with only
"promising" vaccine-induced immunologic responses.
DNA/RNA based
DNA vaccines have been used in the clinical arena to elicit
antigen-specific immune responses. Although nucleic acid
vaccines do not appear to induce as vigorous immune
responses as live viral vaccine vectors, they have several
advantages. Naked DNA is relatively safe, stable, cost effi-
cient, and able to sustain reasonable levels of antigen
expression within cells [for review see [33,34]]
DNA-based plasmid vectors remain stable in a wide range
of conditions over great lengths of time, and they can be
delivered with little risk to individuals who are immuno-
suppressed. In addition, since DNA vaccines do not elicit
neutralizing antibodies in the vaccinated patient, they can
be repeatedly administered with similar efficacy.
The cellular machinery is needed to generate tumour anti-
gens and other necessary proteins are provided by the host
and not required to be incorporated into the vaccine itself.
Finally, the DNA backbone of the injected plasmid con-
tains its own cognate immunostimulatory sequences,
which have been shown to activate innate responses [35].
However, disadvantages to DNA vaccines are their rela-
tively low transfection efficiency and poor immunogenic-
ity. Many strategies have been employed to overcome
these obstacles mostly trying to produce: an efficient
delivery of targeted antigen to antigen presenting cells
such as DCs; an enhancement of antigen processing and
presentation in DCs; and an augmentation of DC and T
cell interaction [36]. Recently, it has been reported that
the fusion of the E7 gene of HPV 16 with a plant virus coat
protein produced strong antitumour activity in a mouse
model activating both CD4+ and CD8+ T cells [37].
A clinical trial with the administration of liposome-encap-
sulated plasmid IL-2 in combination with chemothera-
peutics, was conducted and robust IFN-γ and IL-12 titers
were detected in patients with advanced HNSCC [38].
Similarly, phase I clinical trial using a naked DNA vaccine
encoding the HPV-16 E7 gene linked to M. tuberculosis
HSP70 (pNGVL4a-Sig/E7(detox)/HSP70) is conducting
at the Johns Hopkins Hospital (USA) in patients with
advanced HPV-16 associated HNSCC. The DNA vaccine
was well tolerated and a subset of the vaccinated patients
demonstrated detectable systemic levels of E7-specific
CD8+ T cell immune responses (M. Gillison and T.C. Wu,
personal communication).
Bacterial/viral vectors
Bacteria, such as Listeria monocytogenes, Salmonella, Lac-
tococcus lactis, Lactobacillus plantarum, Bacillus Cal-
mette-Guerin, and several viral vectors, including vaccinia
virus (VV), adenovirus, adeno-associated virus, alphavi-
rus, and its derivative vectors, such as sindbis virus, sem-
liki forest virus, and venezuelan equine encephalitis virus
have been used to deliver genes or proteins of interest to
elicit antigen-specific immunotherapy [for review, [39]].
Among the bacterial vectors, L. monocytogenes has
emerged as a promising vector, because in animal models
it is able to induce both CD8+ and CD4+ immune
responses to elicited regression of established tumours,
and to overcome central tolerance by expanding low avid-
ity CD8+ T cells specific for E7 [40].
Among viral vectors, VV was historically one of the first
viral vector employed in clinical trials of therapeutic vac-
cines against HPV-associated cancer [41]. To date many
VV vaccines have been employed in clinical trials to
deliver genes and antigens of interest efficiently. VV was
utilised to express HPV-16/18 E6/E7 fusion protein,
termed TA-HPV, that was able to induce T cell mediated
immune responses [42-46] or to express HPV E2 protein,
called MVA-E2, that generated a HPV specific cytotoxic
response against the papilloma-transformed cells which
resulted in regression of high-grade lesions [47-49]. The
progression of the genital tumour clinical trials using
these bacterial/viral vectors encoding HPV antigens will
elucidate the possible applicability to the HPV-related
subset of HN cancers.
Plant-derived/produced antigens
Since ancient times plants have been used for therapeutic
purposes, mostly by providing medicinal compounds that
have been extracted and used to treat illness. Nowadays,
plant molecular farming provides new therapeutic possi-
bilities combining the innovations in medical science and
plant biology to create affordable pharmaceutical prod-
ucts. Many methods are available for the antigen produc-
tion and all the TAA antigen in principle can be obtained
with the available technologies [50].
The simple demands for solar light, water and minerals
make plants an easier and more economical system for the
production of heterologous proteins than industrial facil-
ities using fermentation technology. It is estimated that
recombinant proteins can be produced in plants at 2–
10% of the cost of microbial fermentation systems and at
0.1% of the cost of mammalian cell cultures. Yields of
0.1–1.0% total soluble protein are sufficiently competi-
tive with other expression systems to make recombinant
plants economically viable [51]. Moreover, scale-up tech-
nology is available for harvesting and processing plants or
plant products on a large (potentially agricultural) scale.Journal of Experimental & Clinical Cancer Research 2009, 28:69 http://www.jeccr.com/content/28/1/69
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Beside the cost-effectiveness of plant production, plant
derived antigens seem to possess intrinsic activity that
may enhance their immunogenecity. A tumour idiotype-
specific scFv epitope from a mouse B cell lymphoma, that
was produced at high levels in tobacco plants (N. bentha-
miana) and utilized as therapeutic lymphoma vaccine in
subcutaneous immunization, induced an anti-idiotype
immune response and protected mice from challenge by a
lethal dose of syngeneic tumour cells. Interestingly, mice
that received the scFv alone, without adjuvant, showed a
high degree of protection [52], indicating that either the
proper conformation or some other unknown factor pro-
vided by the plant-expression system, improved the effi-
cacy of the immunogen. The same adjuvant-like effect was
noticed when other plant-produced human scFvs (cloned
from tumour biopsy cells), purified from the interstitial
fraction were tested in mice for appropriate anti-idiotype
response [53]. These plant-produced scFvs are currently
undergoing phase I clinical trials. A colorectal cancer anti-
body [54] and a colorectal cancer antigen [55] have been
also produced in N. benthamiana by a TMV-based vector.
The purified plant-derived tumour antigen was able to
stimulate T cells and indicated the presence of some adju-
vant-like effect. Recent data indicate that adjuvant-like
effects were obtained in immunizations with crude plant
extract containing the E7 protein of HPV16. The recom-
binant plant-derived vaccines as 'in planta formulation'
without adjuvants were able to elicit also a protective Th1
cell response in mice [56]. Same adjuvanting activity was
seen with another plant-produced fusion protein of the
HPV16 E7; this antigen preparation was able to induce a
specific CD8+ T stimulation that elicit a therapeutic affect
on experimental tumours [28].
These promising results in pre-clinical models are the
basis to undertake phase I-II clinical trials in HNSCC.
Dendritic cell based
Among specialized APCs the most potent are DCs because
they express high levels of MHC and costimulatory mole-
cules. Therefore on DCs were focused the research of
many investigators and a variety of methods for generat-
ing DCs, loading them with tumour antigens, and admin-
istering them to patients were developed. In fact, in
murine models of HNSCC DCs, pulsed with apoptotic
tumour cells and activated with interleukin-2, induced
strong antigen-specific anti-tumour immunity [57].
Ex vivo loading of DCs may be achieved by proteins or
peptides, or tumour cells, or genomic DNA transfection,
or genetically engineered vectors, or cell fusion tech-
niques. By these methods a pool of uniform, controlled,
and optimally activated APCs can be generated, suggest-
ing a positive utilisation as therapeutic vaccines. Never-
theless the requirement of expensive GMP facilities have
discouraged clinical investigators to implement phase I
trials.
Recent studies have shown that DC therapy produces the
regression of both established carcinomas and haemato-
logic malignancies [58,59].
At least three examples of DC vaccine therapy in HNSCC
have been reported [5]. In the first attempt the DCs were
pulsed with autologous tumour cells but the trial was
interrupted because was quite impossible to obtain 107
tumour cells in sterile conditions for vaccination and the
DTH evaluation of the patients suggested that this strategy
is an unlikely candidate for large scale application. The
second attempt with DCs electroporated with genomic
DNA from autologous tumour cells overcame this prob-
lem and a Phase I trial is in progress. In the third attempt
the DCs were loaded with sequence of wild type (wt) p53
peptides on the basis that the majority of HNSCCC over
express this oncoprotein and clinical trials are underway.
For the subset of HPV-related HN cancers DCs, pulsed
with recombinant HPV-16 and HPV-18 E7 proteins, have
been evaluated in patients with advanced HPV-associated
anogenital cancers [60]. In general, the vaccine was well
tolerated with no significant local or systemic side effects
and HPV antigen-specific T cell responses were observed
in some of the patients [61].
Data from this early stage of clinical development indicate
that a fraction of patients, often less than half, exhibits
immune responses against the vaccinating antigen, indi-
cating that DC vaccines, as other vaccination strategies,
require further improvement, perhaps by exploring the
most effective route of administration, vaccination sched-
ule, prime-boost regimens, and various maturation proto-
cols.
Tumour-cell based vaccines
Although immunization using autologous irradiated
tumour cells can deliver a range of tumour antigens to the
immune system that may not be present in single-target
vaccines and is avoiding the challenges involved in ex vivo
propagation of tumour or immune cells, the poor expres-
sion, processing and presentation of TAA by tumour cell
itself leads to ineffective immunization. Consequently,
studies have focused on strategies to enhance the potency
of cell based vaccines including transduction of tumour
cells with MHC or costimulatory molecules, co-adminis-
tration of adjuvants such as Bacillus Calmette-Guerin, and
engineering tumour cell vaccines to secrete immunostim-
ulatory cytokines.
Among the immunostimulatory cytokines that have been
employed in transducing tumour cells, the GM-CSF
showed the most promising results [for review, [61]]. GM-Journal of Experimental & Clinical Cancer Research 2009, 28:69 http://www.jeccr.com/content/28/1/69
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CSF can be also produced by mixing irradiated tumour cells
with controlled GM-CSF releasing microspheres or
bystander GM-CSF producing cells. Tumour cells have been
also engineered to express MHC and/or co-stimulatory
molecules, such as B7-1 [62,63] in order to activate
immune cells. None of these techniques have been applied
so far to HN cancer, nevertheless tumour-cell based vac-
cines represent an attractive approach which merits further
investigation in order to overcome the hurdle represented
by the need to obtain tumour tissue from each patient.
Adoptive transfer of active T cells
All the above mentioned vaccine preparation can reach a
strong CTL stimulation in vaccinated animals or humans.
However, even high levels of CTL did not correlate with
the presence of active effector cells within the tumours as
the tumour escaping mechanisms are actively fighting the
CTL induced by the TAA utilised for immunotherapy. The
adoptive transfer of active T cells may overcome the
immunotolerance obstacle. This technique relies on the ex
vivo  activation and expansion of tumour-reactive lym-
phocytes which are then returned to the host.
Poorly immunogenic established tumours have been
cured by ACT in murine models [64-66]. Consequently,
similar strategies were transferred into the clinical setting
but early studies demonstrated only partial success [67-
71]. In more recent approaches ACT was utilised together
with strategies to deplete the immune system of endog-
enous T-cell subpopulations like naturally occurring T reg-
ulatory cells or to limit the physical space in transferring
cells [71,72]. By these approaches first successful therapy
was reported in a single patient with melanoma metasta-
sis [73] and thereafter in 35 patients was demonstrated an
objective clinical response in over 50% of them [74,75].
Although these studies, for the first time in humans, dem-
onstrate that ACT is a viable therapeutic strategy, it has to
be pointed out that results were achieved in the setting of
a combined approach with chemotherapy as immu-
nomodulatory agent, indicating the pivotal role of modu-
lating T-reg and suggesting that in this setting even other
vaccine therapy could be efficacious. Furthermore for the
treatment or prevention of HNSCC it is important to note
that ATC as well as DC strategies require cellular products
that are subject to individual patient variability, and the
differences in culture methods, loading strategies, and
injection techniques render these approaches hard to be
transferred to phase II/III studies and posing formidable
challenges to large-scale clinical implementation.
Antibodies against functional molecules of the 
tumour
Targeting HNSCC cell surfaces with high-affinity antibod-
ies is a total different approach that is emerging as advan-
tageous strategy in the development of immunotherapies.
mAb therapy is based on multiple mechanisms of action
including: inhibition of ligand induced activation; induc-
tion of receptor degradation or complement-mediated/
antibody-dependent cellular cytotoxicity; activation of
tumour-specific CTL via cross-priming of lysed tumour
cells; and finally delivering of a conjugated chemothera-
peutic toxin to the tumour bed when linked to the anti-
body [76-78].
To date, most of the mAb therapies target the EGFR as this
receptor is overexpressed in more than 90% of HNSCC
[for review, [6,79]].
Cetuximab, a chimeric IgG1 isotype murine/human epi-
dermal growth factor receptor-specific monoclonal anti-
body, as well as has Panitumumab, a fully humanized
IgG2 isotype monoclonal antibody, have been approved
by the US Food and Drug Administration, and their clini-
cal efficacy is well documented [80]. It is possible that
these monoclonal antibodies, employed to block the sig-
nalling pathways, may also serve as immunostimulants.
The Fc portion of monoclonal antibodies binds to the Fcγ
receptor (FcγR) of effector cells like natural killer cells,
macrophages/monocytes, and other granulocytes, recruit-
ing these cells that participate in antibody-dependent cel-
lular cytotoxicity by the release of lytic mediators for the
target cells. Indeed, polymorphisms in the Fcγ receptor
can predict clinical outcomes in patients with metastatic
colorectal cancer receiving cetuximab therapy [81].
Antibodies that may have an immunostimulatory compo-
nent have been developed against another overexpressed
tumour antigen, the vascular endothelial growth factor
(VEGF) which is a tumour secreted molecule that stimu-
lates angiogenesis and lymphangiogenesis. High expres-
sion of VEGF and its receptor was detected and associated
with poor survival in patients with head and neck cancers
[82]. Bevacizumab is a recombinant humanized anti-
VEGF mAb which is currently being evaluated in several
tumours with promising results but only in term of trends
[for review, [81]]. This therapy has yet to be explored in
head and neck cancers.
Finally antibodies can be targeted to molecules involved
in immune modulation. In mice antitumour immunity
was achieved by antibodies against the CTLA4 molecule
that is a ligand expressed by T lymphocytes that functions
to inhibit T-cell activation by binding to B7.1 and B7.2,
thereby preventing CD28 from binding to B7 [83].
The brilliant results of a phase 1 clinical trial using a fully
humanized antagonistic CTLA4 monoclonal antibody
highlight the potential immunotherapeutic value of anti-
body-based therapies for cancer [16].Journal of Experimental & Clinical Cancer Research 2009, 28:69 http://www.jeccr.com/content/28/1/69
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Future challenges and progresses
The introduction in the clinical practice of two highly effi-
cacious preventive vaccines [84,85] (Gardasil MSD, and
Cervaix GSK) against HPV opens a new scenario suggest-
ing a role of this vaccination in the preventive therapy of
the subset of HNSCC linked to HPV infection, hypothesis-
ing a preventive immunological approach for other
tumours. Trials to evaluate prevention require greater
numbers of participants, longer follow-up to evaluate
meaningful endpoints, and raise different ethical issues
than therapeutic studies. However it is predictable that
not all tumours can beneficiate of this preventive
approach, stressing the need for cancer immunotherapies.
Cancer vaccines are a powerful example how is wrong to
approach to scientific problems by optimism or pessi-
mism about the initial results. The degree of optimism or
pessimism associated with researches into therapeutic
cancer vaccines depends largely upon definitions of
response to treatment. If you use objective complete
response and partial response to cancer vaccines as indi-
cated by World Health Organization (WHO) [86] the pes-
simism is compulsory; if you consider the Response
Evaluation Criteria in Solid Tumours (RECIST) [87] cau-
tious optimism or less pessimism is conceivable, whereas
if less objective so-called "soft" criteria are employed (e.g.
minor response, stable disease, clinical benefit) are
employed the optimism about immunotherapy predomi-
nates.
Data of phase I-II trials with these large arrays of therapeu-
tic vaccines indicate their efficacy in elicit some immuno-
logical response, and only few phase III trials reported
success in the therapy having the RECIST as end point.
In a recent reviews for all type of tumours a percentage of
only 2.9% of clinical response to therapeutic vaccines was
reported [88,89]. However, results from cancer immuno-
therapy must be viewed in the context of the patient pop-
ulations included in trials. Indeed, response rates will be
low if the enrolled patients have metastatic disease with
failure after standard therapies [90].
Therefore the pessimistic and simply conclusion that can-
cer vaccines have been tested and failed may be wrong.
Only in relative short time the knowledge on immunoto-
lerance and tools to overcome it have been achieved,
emphasizing the need for profound changes in the appli-
cation of immunotherapy.
Firstly, investigators have to concentrate their efforts in:
￿ Generating antitumour CD4+ cells that enhance
antitumour reactions and sustain the activation and
survival of CD8+ cells.
￿ Activating innate immunity by new toll-like [91]
receptor agonists.
￿ Targeting TAA that are essential for tumour cell sur-
vival.
￿ Stimulating inflammatory response/environment at
the tumour site.
￿ Utilising adjuvated antigens to activate quiescent
cells (e.g. with costimulatory molecules).
￿ Blocking negative costimulatory molecule (the
already reported efficacy of anti CTLA-4 monoclonal
antibodies holds promise for this approach [for
review, [92]).
￿ Finally eliminating both tumour and Treg-mediated
immune suppressive mechanisms without adversely
affecting effector cells, that recent evidence indicates as
the most importantly achievement [93].
Secondly, wide-scale evaluation and clinical application
of cellular-based vaccines are limited by factors such as
product uniformity and the significant resources neces-
sary for successful production. Efforts must be done in
order to overcome the technology obstacles limiting the
development of T-cell based vaccines as standardized rea-
gents. Moreover even the other immunotherapeutic
approaches need the development of standardized proce-
dures and vaccines to be evaluated in multi-institutional
studies. The future success of immunotherapy will depend
mostly on standardization.
Thirdly, when used in the therapeutic setting, it is now
clear that antitumour immunity can be augmented by
ancillary approaches such as prime-boost strategies, or
multivalent vaccines, or the use of chemotherapeutics or
molecules which regulate costimulatory functions or dif-
ferent route of delivery. The last issue may hold promise
as a mean of enhancing vaccine efficacy. Classical antimi-
crobial vaccination strategies have relied on subcutaneous
or intramuscular injections to stimulate long-lasting
immunity. However, it is now clear that the route of vac-
cination impacts both the potency and location of
immune response generated. DNA immunization elicits
completely different response if the same antigen encod-
ing plasmid is injected intradermally, subcoutaneously or
intramuscularly. In mouse model, subcutaneous injection
of DC causes the T-cell responses and the localization of
DC into the draining lymph nodes whereas intravenous
administration does not [94]. Intratumoural boosting
shots produce better antigen-specific T-cell responses
[95]. In the clinical setting, various studies indicated that
DNA vaccines [96], DC [97], or autologous tumour cellsJournal of Experimental & Clinical Cancer Research 2009, 28:69 http://www.jeccr.com/content/28/1/69
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[98] delivered by intranodal and intralymphatic injec-
tions yielded improved CTL responses in cancer patients.
Oral administration is another fascinating hypothesis of
tumour vaccination as well as the utilisation of edible vac-
cines and, in this issue, some evidence is coming out [50].
However, only a small number of studies have correlated
vaccination route with memory T-cell function and there-
fore efforts must be done in introducing this variable in
the experimental setting
Conclusion
While immune therapy for the treatment of cancer holds
promise, current cancer vaccines have broad limitations
and few objective clinical responses.
Nevertheless immunotherapy can be successful in cancer
patients and thus increased effort in the development of
cancer immunotherapy is needed. Further clinical studies
should utilize standard criteria for clinical response and
require validation in increased numbers of patients.
Now, where are we? We have climbed the K2 mountain
(the individuation of useful TAA and of vaccine settings
able to induce CTL response) and we are climbing the
Everest mountain (the tumour immunotolerance and
immune escape).
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